PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients - Trial NCT06359275
Access comprehensive clinical trial information for NCT06359275 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 81 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fudan University
Timeline & Enrollment
Phase 2
Apr 01, 2024
Oct 01, 2027
Primary Outcome
Progression-free survival (PFS)
Summary
This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody
 (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR
 radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients
 with only local recurrence after pancreatic cancer surgery, to observe the safety and
 efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type)
 and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable
 pancreatic cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06359275
Non-Device Trial